American Association for Cancer Research
Browse
15417786mcr100233-sup-supplementary_data.pdf (599.82 kB)

Supplementary Data from Chk1-Dependent Constitutive Phosphorylation of BLM Helicase at Serine 646 Decreases after DNA Damage

Download (599.82 kB)
journal contribution
posted on 2023-04-03, 18:06 authored by Sarabpreet Kaur, Priyanka Modi, Vivek Srivastava, Richa Mudgal, Shweta Tikoo, Prateek Arora, Debasisa Mohanty, Sagar Sengupta

Supplementary Figures S1-S4 and Supplementary Tables S1-S2.

History

ARTICLE ABSTRACT

BLM helicase, the protein mutated in Bloom syndrome, is involved in signal transduction cascades after DNA damage. BLM is phosphorylated on multiple residues by different kinases either after stress induction or during mitosis. Here, we have provided evidence that both Chk1 and Chk2 phosphorylated the NH2-terminal 660 amino acids of BLM. An internal region within the DExH motif of BLM negatively regulated the Chk1/Chk2-dependent NH2-terminal phosphorylation event. Using in silico analysis involving the Chk1 structure and its known substrate specificity, we predicted that Chk1 should preferentially phosphorylate BLM on serine 646 (Ser646). The prediction was validated in vitro by phosphopeptide analysis on BLM mutants and in vivo by usage of a newly generated phosphospecific polyclonal antibody. We showed that the phosphorylation at Ser646 on BLM was constitutive and decreased rapidly after exposure to DNA damage. This resulted in the diminished interaction of BLM with nucleolin and PML isoforms, and consequently decreased BLM accumulation in the nucleolus and PML nuclear bodies. Instead, BLM relocalized to the sites of DNA damage and bound with the damage sensor protein, Nbs1. Mutant analysis confirmed that the binding to nucleolin and PML isoforms required Ser646 phosphorylation. These results indicated that Chk1-mediated phosphorylation on BLM at Ser646 might be a determinant for regulating subnuclear localization and could act as a marker for the activation status of BLM in response to DNA damage. Mol Cancer Res; 8(9); 1234–47. ©2010 AACR.